Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain

References

• Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3–11
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9–15
   Google Scholar
• Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27;1458–1486
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956–962
   PubMed Web of Science ®Google Scholar
• Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21;976–982
   PubMed Web of Science ®Google Scholar
• Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156–162
   PubMed Web of Science ®Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12–25
   Google Scholar
• Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123–128
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374–385
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272–2280
   PubMed Web of Science ®Google Scholar
• Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518–1522
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892–900
   PubMed Web of Science ®Google Scholar
• Jude EB, Jacob K. Managing painful neuropathy in diabetes. Pol Arch Med Wewn 2008;118:260–261
   PubMedGoogle Scholar
• Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. Pain Med 2007;8:S33–42
   PubMedGoogle Scholar
• Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med 2007;8:S27–32
   PubMed Web of Science ®Google Scholar
• Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007;21:306–314
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672–679
   PubMed Web of Science ®Google Scholar
• Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007;67:569–585
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA) guideline. All About Diabetes. 2008;. Available at: http://www.diabetes.org/home.jsp
   Google Scholar
• Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;(Suppl):3–19
   Google Scholar
• Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399–407
   PubMed Web of Science ®Google Scholar
• Cymbalta(R) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2004
   Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105–116
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565–774
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Index, January 2008
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619
   PubMed Web of Science ®Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
   Google Scholar
• Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or count responses. Annu Rev Public Health 2007;28:95–111
   PubMed Web of Science ®Google Scholar
• Efron B, Tibhirani R. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993
   Google Scholar
• Gatti ME, Jacobson KL, Gazmararian JA, et al. Relationships between beliefs about medications and adherence. Am J Health Syst Pharm 2009;66:657–664
   PubMed Web of Science ®Google Scholar
• Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206–213
   PubMed Web of Science ®Google Scholar
• Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8:S50–62
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19:516–521
   Google Scholar
• Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007;24:187–194
   PubMed Web of Science ®Google Scholar